ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2584

Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs

Jonathan Kay1, Joshua Rancourt2, John D. Bradley2, Vipin K. Arora2, Jinglin Zhong3, Christina Dickson2 and David Muram2, 1Rheumatology Center, Memorial Campus, UMass Memorial Medical Center, Worcester, MA, 2Eli Lilly and Company, Indianapolis, IN, 3Quintiles, Rockville, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: rheumatic disease and rheumatoid arthritis (RA), Rheumatology

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:   Anemia in rheumatoid arthritis (RA) patients (pts) has a prevalence of 16%-64% depending on population and severity of disease1,2,3 and is more common in women, pts with seropositive and erosive disease, and pts treated with systemic corticosteroids.2 This post hoc analysis was performed to determine prevalence of anemia in a contemporary cohort of RA pts treated with conventional disease-modifying antirheumatic drugs (cDMARDs).

Methods:   Data were pooled from screening for 2 phase 3 trials conducted from Oct 2012 to Sept 2015 in RA pts inadequately responsive to cDMARDs. Eligibility included ≥6/68 tender and ≥6/66 swollen joints. One study required erosions on radiographs and high-sensitivity C-reactive protein (hsCRP) ≥6 mg/L; the other required hsCRP ≥1.2x upper limit of normal (ULN), or 3.6mg/dL. Prior biologic disease-modifying antirheumatic drugs were prohibited. Analysis included data from pts who failed screening for any reason, such as hsCRP or number of tender or swollen joints below threshold for study entry. Anemia was defined as hemoglobin (Hgb) <8 g/dL, <10 g/dL, or below the age- and gender-adjusted lower limit of normal (gaLLN).

Results:   Analysis included 3925 screened pts: 3159 women and 766 men, including 1591 women and 345 men who failed screening. Hgb <8 g/dL was observed in 8 women (0.3%). Hgb <10 g/dL was seen 10x more frequently in women, occurring in 128 women (4.1%) and 3 men (0.4%). When the less stringent definition of <gaLLN was used, anemia was identified in 718 women (22.7%) and 185 men (24.2%). Prevalence of Hgb <gaLLN was 24% among pts ≤65 years and 16% among pts >65 years. Anemia (<gaLLN definition) was more prevalent among pts with more active disease. Using Simplified Disease Activity Index, prevalence of Hgb <gaLLN in pts who met screening criteria was 0% in pts in remission or with low disease activity, 3.37% in pts with moderate disease activity, and 21.8% in pts with high disease activity. Analysis by tertiles of acute phase reactant levels (hsCRP or erythrocyte sedimentation rate) yielded similar findings.

Conclusion:   In a contemporary population of pts with active RA treated with cDMARDs, prevalence of Hgb <10 g/dL was low, but 10x more frequent in women. When anemia was defined as Hgb <gaLLN (rather than as Hgb <10), prevalence was higher in men and women, regardless of age. Hgb <gaLLN was observed more often in pts with more active RA. Inclusion of pts with RA who failed to meet entry criteria of these clinical trials allows assessment of the prevalence of anemia in an RA population treated with cDMARDs. References

  1. Short CL, Bauer W, Reynolds WE. Red-cell, white-cell, and differential counts. In: Rheumatoid Arthritis. Cambridge, MA: Harvard University Press, 1957:349-356.
  2. Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis 1996;55(3):162-8
  3. Furst DE, Chang H, Greenberg JD, et al. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: Evidence from the CORRONA registry. Clin Exp Rheumatol 2009;27(4):560-6.


Disclosure: J. Kay, AbbVie Inc.; Ardea Biosciences, Inc.; Eli Lilly and Company; Pfizer Inc.; Genentech Inc.; Roche Laboratories, Inc., UCB, Inc., 2,Alexion Pharmaceuticals; Amgen, Inc.; AbbVie Inc.; AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Crescendo Bioscience, Inc.; Eli Lilly and Company; Epirus Biopharmaceuticals, Inc.; Fast Forward Pharmaceuticals, B.V.; Genentech Inc., 5; J. Rancourt, Eli Lilly and Company, 1,Eli Lilly and Company, 3; J. D. Bradley, Eli Lilly and Company, 1,Eli Lilly and Company, 3; V. K. Arora, Eli Lilly and Company, 1,Eli Lilly and Company, 3; J. Zhong, Quintiles, 3; C. Dickson, Eli Lilly and Company, 1,Eli Lilly and Company, 3; D. Muram, Eli Lilly and Company, 1,Eli Lilly and Company, 3.

To cite this abstract in AMA style:

Kay J, Rancourt J, Bradley JD, Arora VK, Zhong J, Dickson C, Muram D. Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-anemia-among-rheumatoid-arthritis-patients-treated-with-conventional-disease-modifying-antirheumatic-drugs/. Accessed January 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-anemia-among-rheumatoid-arthritis-patients-treated-with-conventional-disease-modifying-antirheumatic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.